A Study of TQ-B3101 Capsules in Subjects With Advanced Malignant Tumor
The objective of this study is to evaluate efficacy and safety of TQ-B3101 in subjects with advanced malignant tumor.
Advanced Malignant Tumor
DRUG: TQ-B3101
Overall response rate (ORR), Percentage of subjects achieving complete response (CR) and partial response (PR)., up to 48 weeks|Adverse events (AE) and serious adverse events (SAE), The occurrence of all adverse events (AE) and serious adverse events (SAE)., up to 48 weeks
Progression free survival (PFS), PFS defined as the time from first dose until the first documented progressive disease (PD) or death from any cause., up to 48 weeks|Disease control rate (DCR), Percentage of participants achieving complete response (CR) and partial response (PR) and stable disease (SD)., up to 48 weeks|Overall survival (OS), OS defined as the time from randomization to death from any cause. Participants who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive., up to 48 weeks
The objective of this study is to evaluate efficacy and safety of TQ-B3101 in subjects with advanced malignant tumor.